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PRole of Rac1 GTPase Activation in Atrial Fibrillation
Oliver Adam, MD,* Gregg Frost,* Florian Custodis, MD,* Mark A. Sussman, PHD,‡
Hans-Joachim Schäfers, MD,† Michael Böhm, MD,* Ulrich Laufs, MD*
Homburg/Saar, Germany; and San Diego, California
Objectives We aimed to study the role of Rac1 GTPase in atrial fibrillation (AF).
Background The signal transduction associated with AF is incompletely understood. We hypothesized that activation of Rac1
GTPase contributes to the pathogenesis of AF via activation of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase and production of reactive oxygen species.
Methods Old mice with cardiac-specific overexpression of constitutively active V12Rac1 (RacET) were compared with wild-type
(WT) and WT undergoing transaortic constriction (TAC). In addition, samples of human left atrial appendages were
analyzed in patients with sinus rhythm (SR) compared with patients with permanent AF matched for atrial diameter.
Results At age 16 months, 75% of RacET but no WT or TAC mice showed AF. Treatment of RacET with statins for 10 months
did not alter weight or fibrosis of atria or ventricles but decreased cardiac Rac1 and NADPH oxidase activity and re-
duced the incidence of AF by 50%. The left atria of patients with AF showed increased fibrosis, up-regulation of NADPH oxi-
dase activity, a 4-fold increase of Rac1 total protein and membrane expression as well as up-regulation of Rac1 activity.
Conclusions Chronic cardiac overexpression of Rac1 represents a novel mouse model for AF. Rac1 GTPase contributes to the
pathogenesis of AF and identifies a target for the prevention and treatment of AF. (J Am Coll Cardiol 2007;50:
359–67) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.041t
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Rtrial fibrillation (AF) is the most common arrhythmia (1).
he prevalence of AF is estimated at 0.4% of the general
opulation, increasing with age to 6% in those over 80
ears. Atrial fibrillation is associated with many forms of
ardiac pathology, including coronary artery disease, heart
ailure, arterial hypertension, valvular disease, and cardiac
urgery, but a substantial proportion of patients with AF
ave no detectable heart disease. Hemodynamic impairment
nd thromboembolic events related to AF result in signifi-
ant morbidity, mortality, and cost. Atrial fibrillation is
ssociated with atrial structural remodeling due to intersti-
ial fibrosis. Other factors potentially involved in the induc-
ion or maintenance of AF include focal inflammation,
ndothelial/endocardial dysfunction, ischemia, and auto-
omic nervous system activity, but the detailed signal trans-
uction leading to AF is incompletely understood (1,2).
Recent evidence shows that increased atrial oxidative
tress might play an important role in inducing and main-
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upported by the Deutsche Forschungsgemeinschaft (to Dr. Laufs) and the Univer-
ität des Saarlandes (HOMFOR).(
Manuscript received January 9, 2007; revised manuscript received February 15,
007, accepted March 5, 2007.aining AF in animal models and humans (3–5). Atrial
brillation induced by rapid atrial pacing in pigs is charac-
erized by increased nicotinamide adenine dinucleotide
hosphate (NADPH) oxidase activity and superoxide pro-
uction in the left atrium (LA) (5). Right human atrial
ppendages of patients with AF exhibit higher levels of the
xidative markers 3-nitrotyrosine and protein carbonyls
ompared with patients with sinus rhythm (SR) (4). In the
eft ventricle (LV), myocardial oxidative stress is mediated,
n part, by increased activity of the superoxide producing
icotinamide NADPH oxidase. The Rho GTPase Rac1
egulates NADPH oxidase activity and is critical for gen-
rating oxidative stress and producing cardiac LV hypertro-
hy (6–9). However, the role of Rac1 GTPase in atrial
yocardium and during AF is not known.
We hypothesized that activation of Rac1 GTPase might
ontribute to the pathogenesis of AF via activation of
uperoxide producing NADPH oxidase. To address this
ypothesis we studied a transgenic mouse model of cardiac-
pecific overexpression of Rac1 and analyzed left atrial
yocardium from patients with AF.
ethods
nimal studies. The characteristics of transgenic mice
ith cardiac overexpression of constitutively active (V12)
ac1 under the control of the alpha-myosin heavy chainMHC) promoter (RacET) and wild-type control subjects
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ously (10). Mice were fed with
normal chow (ssniff, Soest, Ger-
many) or normal chow supple-
mented with 0.4 mg/d of com-
mercially available rosuvastatin
(Crestor, AstraZeneca, London,
United Kingdom). The study
was not funded by the pharma-
ceutical industry. Rosuvastatin
was chosen because of previous
experience with this drug in mice
(6). Heart rate, regularity, and
presence of P waves were docu-
mented by 2 electrocardiography
(ECG) recordings (Schwarzer
CU 12 system, Picker, Munich,
Germany) on the day before and
on the day of sacrifice. Transtho-
acic echocardiography (GE Systems Vivid 5 scanner, 13
Hz transducer; Waukesha, Wisconsin) was performed in
ll mice. Transverse aortic constriction (TAC) or sham
peration was performed at age 10 weeks in male animals as
escribed (6). Pulmonary and hepatic congestion were
efined as wet weight  dry weight. The study was
pproved by the animal ethics committee of the Universität
es Saarlandes and is in accord with the Guide for the Care
nd Use of Laboratory Animals published by the U.S.
ational Institutes of Health (NIH pub. no. 85-23, revised
996).
uman left atrial tissue. Tissue samples of the left atrial
ppendage of patients undergoing mitral valve surgery were
nalyzed in 7 consecutive patients with SR and 8 patients
ith permanent AF (documented by ECG for 3 months)
atched for atrial diameter, left ventricular function, and
edication. The patients did not receive drugs at least 12 h
efore surgery. Standardized echocardiography of all pa-
ients was obtained before surgery. Myocardial tissue was
mmediately frozen and stored at 80°C. The study of
uman myocardial tissue was approved by the ethics com-
ittee of the A¨rztekammer des Saarlandes (no. 131/00).
ADPH oxidase activity. The NADPH oxidase activity
as measured by a lucigenin-enhanced chemiluminescence
ssay as described (6).
estern analysis. For membrane preparation, tissue ly-
ates were pelleted by low-speed centrifugation and lysed in
ypotonic medium buffer (containing protease inhibitors [in
g/ml] phenylmethylsulfonyl fluoride 10, leupeptin 2, pep-
tatin A 2, and aprotinin 2) followed by 30 strokes of a
las-teflon homogenizer on ice. Nuclei were removed from
he homogenate by centrifugation at 95 g (Biofuge pico;
eraeus, Kendro, France, r  7 cm, 1,100 rpm) for 5 min
t 4°C. The low-speed supernatant was then pelleted by
entrifugation at 100,000 g (36,000 rpm, Beckman Ti-60.1,
 6.9 cm) at 4°C in a Beckman L8-M preparative
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiography
LA  left atrium
LV  left ventricle
NADPH  nicotinamide
adenine dinucleotide
phosphate
RacET  transgenic mice
with cardiac
overexpression of Rac1
GTPase
SR  sinus rhythm
TAC  transverse aortic
constriction
WT  wild-type miceltracentrifuge (Beckman Instruments, Inc., Palo Alto, ualifornia). Separation of cytosolic and membrane proteins
as controlled by Western blotting with GAPDH (6C5,
c-32233, Santa Cruz Biotechnology, Santa Cruz, Califor-
ia). Immunoblotting was performed with Anti-Rac1 (Up-
tate, Waltham, Massachusetts; clone 23A8), -Actin (1:
50 dilution, Santa Cruz Biotechnology), and goat anti-
abbit or goat anti-mouse secondary antibody (1:4,000
ilution, Sigma, St. Louis, Missouri) and an enhanced
hemiluminescence kit (Amersham Biosciences, Pittsburgh,
ennsylvania) followed by densitometry (6,7,11). Expres-
ion was calculated with a standard curve generated with
ecombinant Rac1 protein (Upstate).
ac1 GST–p21-activated kinase pull-down assay. Tissue
as homogenized and resuspended in magnesium-
ontaining lysis buffer (25 mmol/l HEPES [pH 7.5]; 150
mol/l sodium chloride; 1% Igepal CA-630; 10% glycerol;
5 mmol/l sodium fluoride; 10 mmol/l magnesium chloride;
mmol/l EDTA; 1 mmol/l sodium orthonvanadate; 10
g/ml leupeptin; 10 g/ml aprotinin) and centrifuged at 78
(Biofuge pico Heraeus, r  7 cm, 1,000 rpm) for 5 min at
°C. Equal amounts of supernatant protein were incubated
ith 10 l of agarose labeled p21-activated kinase (PAK)-1
usion protein (Upstate) at 4°C for 60 min. Beads were
ashed 3 times with magnesium-containing lysis buffer,
luted in Laemmli buffer (60 mmol/l Tris [pH 6.8], 2%
odium dodecylsulfate, 10% glycerin, 0.1% bromphenol
lue) and analyzed for bound Rac1 in relation to total Rac1
ontent by Western blotting.
istologic analysis. Ten-micrometer cryosections were
xed in acetone, and total collagen was stained with 0.1%
irius Red F3BA (Polysciences, Warrington, Pennsylvania)
n a saturated picric acid solution for 15 min followed by
ashing in aqua dest and rapid dehydration in 100% alcohol
nd xylene. For morphometric analysis, all sections were
xamined under a Nikon E600 microscope (Nikon, Tokyo,
apan). Lucia Measurement (Nikon, Duesseldorf, Ger-
any) version 4.6 software was used for quantification of
nterstial fibrosis.
tatistical analysis. Band intensities were analyzed by
ensitometry. All values are expressed as mean  SEM.
npaired Student t tests and analyses of variance for
ultiple comparisons were applied. Post hoc comparisons
ere performed with the Bonferroni test. The significance
f the correlation of Rac1 activity with NADPH oxidase
ctivity was calculated with the Pearson’s chi-square test.
he SPSS (SPSS Inc., Chicago, Illinois) software, ver-
ion 12.0, was used. Differences were considered signif-
cant at p  0.05.
esults
F in mice over-expressing Rac1 in the heart. To test the
ole of Rac1 in the pathogenesis of AF, we studied the
ong-term effect of overexpression of Rac1 in mice with
ardiac overexpression of constitutively active (V12) Rac1
nder the control of the alpha-MHC promoter (RacET)
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July 24, 2007:359–67 Rac1 GTPase in AFn  10 to 15) (10). These mice show 2 distinct cardio-
yopathic phenotypes: a lethal dilated phenotype associated
ith neonatal activation of the transgene; and a cardiac
ypertrophy with survival comparable to WT, which was
tudied here. Concentric hypertrophy was evident in
-week-old RacET ventricles (10). Hypertrophic character-
stics diminish as the mice age, but echocardiography at age
6 months showed a persistent concentric hypertrophy
ompared with WT and the ratio of heart weight/tibia
ength was increased (Table 1, Fig. 1). Functionally, RacET
xhibited decreased fractional shortening compared with
T, but pulmonary and hepatic congestion as indicators of
ymptomatic heart failure were not significantly increased
Table 1, Fig. 1). Because the aim of the study was to
haracterize the role of Rac1 in AF, a control group of WT
ice was subjected to TAC to differentiate the effect of
ressure-induced ventricular hypertrophy and secondary
ac1 activation on the atrial phenotype from the primary
ardiac over-expression of Rac1 in RacET mice. At the age
f 16 months, TAC mice showed concentric hypertrophy,
ecreased fractional shortening and increased pulmonary
ongestion compared with WT (Table 1, Fig. 1). In the
tria, a differential effect of long-term pressure-induced
entricular hypertrophy and transgenic cardiac Rac1 over-
xpression on morphology and function was observed: the
acET mice showed significantly greater atria in relation to
eart weight and tibia length compared with both WT and
AC (Table 1, Fig. 1G). Importantly, ECG revealed that
5% of 16-month-old RacET mice had AF, but all WT and
AC mice showed SR.
ncreased atrial collagen and NADPH oxidase activity in
acET mice. Interstitial collagen content quantitated by
irius red staining was significantly increased in the atria of
acET (44  1% of area) compared with WT (19  5%,
 0.05). The extent of interstitial fibrosis in TAC atria
31  6%) was in between WT and RacET but did not
ignificantly differ from either group (Fig. 2). In the LV,
oth RacET and TAC mice showed elevated collagen
haracteristics of WT, RacET, and TAC Mice After 16 Months
Table 1 Characteristics of WT, RacET, and TAC Mice After 16
WT SEM R
Heart rate (beats/min) 216.0 5.1
Mouse (g) 23.1 0.4
Tibia (mm) 16.6 1.4
Heart (mg) 131.0 1.5
Atria (mg) 10.3 1.0
LV (mg) 92.6 11.6
RV (mg) 15.1 1.2
Pulmonary congestion (l) 151 15.7
Hepatic congestion (l) 751 113.3
Heart (mg)/tibia (mm) 7.7 0.7
Atria (mg)/tibia (mm) 0.6 0.0
Atria (mg)/heart (mg)/tibia (mm) 4.6 0.2
ransgenic mice with cardiac overexpression of constitutively active (V12) Rac1 under the control of
ortic constriction (TAC16); n  10. *Significant versus WT; †significant versus RacET16.
LV  left ventricle; RV  right ventricle.ontent compared with the control group (WT 9  2%,
acET 29  3%, p  0.005 vs. WT; TAC 24  4%, p 
.05 vs. WT). In all mice, atrial collagen content exceeded
entricular collagen.
Short term TAC has been shown to increase myocardial
ADPH oxidase activity (6,9). Old TAC mice (16 months)
isplayed equal basal NADPH oxidase activity compared
ith WT control subjects but showed 2-fold greater
ADPH oxidase activity upon stimulation with angiotensin
I, 10 mol/l, 10 min. In contrast, RacET mice exhibited
arkedly increased basal as well as angiotensin II stimulated
ADPH oxidase activity (443  213% and 571  109%,
espectively, p  0.05) (Fig. 2D).
eduction of Rac1 activity by statin decreases AF. Oral
reatment with rosuvastatin (0.4 mg/d) was initiated on the
ay before TAC. At the age of 10 months, atria of RacET
ere moderately enlarged compared with WT (19.4  1.3
g vs. 10.1  1 mg) but considerably smaller compared
ith 16-month-old RacET (41.2  8.1 mg) (Tables 1
nd 2). Treatment of RacET with statin did not alter the
eight of atria or ventricles (n  10 to 15/group) (Table 2).
s expected in the model, cardiac Rac1 activity was strongly
ncreased by approximately 30-fold in RacET compared
ith WT. Despite transgenic expression of constitutively
ctive V12Rac1, statin treatment reduced Rac1 activity to
6  3.5% of vehicle treated RacET (p  0.05) (Fig. 3A).
he Rac1 total protein expression was not changed, how-
ver, Rac1 membrane expression was decreased to 76  9%
Figs. 3B and 3C). Echocardiography showed a small but
ignificant increase of fractional shortening and decreased
V wall thickness and slightly increased left ventricular
nd-diastolic diameters in the statin-treated group (Figs. 3D to
H). Reduction of Rac1 activity by statin treatment was
ssociated with a reduced incidence of AF by approximately
0% (20% in RacET statin vs. 44% AF in RacET, p 0.05)
Fig. 4A). Atrial collagen content was not reduced in the statin
roup (Figs. 4C and 4D). Statin treatment inhibited basal
ADPH oxidase activity in 10-month-old RacET mice (215
hs
6 SEM TAC16 SEM p Value
30.5 173.3 33.3 NS
* 0.7 28.1* 3.3 0.03
0.2 17.3 0.5 NS
* 10.6 272.8* 31.2 0.03
* 8.1 30.3 6.5 0.05
11.3 173.7* 18.6 0.01
1.8 24.9* 2.8 0.03
12.1 258*† 35.1 0.01
29.9 1,024 95.6 NS
* 0.6 15.8* 1.7 0.005
* 0.5 1.7 0.4 0.03
* 1.9 6.3 1.1 0.05
ha-myosin heavy chain promoter (RacET16) compared with wild-type (WT) andWT after transverseMont
acET1
273.8
27.5
17.3
216.0
41.2
121.6
20.2
155
994
12.4
2.3
10.9
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Rac1 GTPase in AF July 24, 2007:359–6737% vs. 75  12% of WT control, p  0.05) as well as
ngiotensin II–induced NADPH oxidase activity (654 
60% vs. 186  21% of WT control, p  0.05) (Fig. 4E).
ac1 activity directly correlated with stimulated NADPH
xidase activity (R  0.84, p  0.05).
Figure 1 RacET Mice Develop
Atrial Dilatation and Atrial Fibrillation
(A) Representative cross sections of the left ventricle (LV), and (B) M-mode
echocardiographic images of the LV of wild-type (WT), transgenic mice with car-
diac overexpression of Rac1 GTPase (RacET)16, and transaortic constriction
(TAC)16 mice. Quantification of measurements of (C) fractional shortening
(FS); (D) diastolic interventricular septum (IVSd); (E) diastolic left posterior wall
(LPWd); and (F) left ventricular end-diastolic diameter (LVDd); n  6, 5 sepa-
rate measurements/animal. (G) Ratio of weight of atria to total heart and tibia
length. (H) Incidence of atrial fibrillation (AF), and (I) representative electrocar-
diography recording. n  10, *p  0.05 compared with WT.ncreased collagen and NADPH-oxidase activity in hu-
an left atria in AF. To test the role of Rac1 GTPase in
uman AF, tissue samples of the left atrial appendage of
atients undergoing mitral valve surgery were analyzed in 7
onsecutive patients with SR and 8 patients with permanent
F matched for atrial diameter, left ventricular function,
nd medication. Patient characteristics are summarized in
able 3. The size of the LA was measured before surgery by
chocardiography and did not differ between groups (52.7
mm vs. 52.14  3.7 mm). Interstitial fibrosis was
etermined by Sirius red staining. In the LA of patients
ith AF, collagen content was significantly higher com-
ared with SR (14.9  2.1% vs. 8.5  1.3%, p  0.05)
Fig. 5). In unstimulated LA tissue, the activity of the
uperoxide-producing NADPH-oxidase did not differ be-
Figure 2 RacET Mice Exhibit Increased
Atrial Fibrosis and NADPH-Oxidase Activity
(A) Representative Sirius red staining (10- and 100-fold magnification) in the
left atrium (LA) and the LV in WT, RacET16, and TAC16. (B) Quantification of
interstitial fibrosis in the LA and (C) the LV. n  10, *p  0.05 versus WT, #p
 0.05 versus TAC16. (D) Atrial nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activity at baseline and after exposure to angiotensin II (Ang),
1 mol/l, 10 min, in WT, RacET16, and TAC16; n  6, *p  0.05 versus WT,
#p  0.05 versus TAC16. Abbreviations as in Figure 1.
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July 24, 2007:359–67 Rac1 GTPase in AFween SR and AF (Fig. 5C). However, after pre-incubation
ith phorbol-12-myristate13-acetate (PMA), 1 mol/l, 10
in, LA from patients with AF showed a 4-fold up-
egulation of NADPH oxidase activity compared with atria
rom SR patients stimulated with PMA (p  0.01).
ctivation of Rac1 GTPase in human left atria in
F. Animal experiments have shown that Rac1 GTPase is
regulator of NADPH oxidase activity in the LV. Expres-
ion of atrial Rac1 is not known. Therefore, Rac1 expression
nd activity was assessed in human LA. Western analysis
howed an increase of Rac1 total protein expression in AF
o 361  47% (p  0.001) compared with SR (Figs. 5D,
E, 5F, and 5G). The cell membrane is the main site of
ac1 function. The membrane content of Rac1 was up-
egulated to 428  146% in LA from patients with AF
p  0.05) compared with SR. The cytosolic expression of
ac1 was unchanged. With an affinity binding assay with
he Cdc42 and Rac1 interactive binding domain from
AK1B as pull-down probe for Rac1-GTP, we investigated
ac1-GTPase activity. Figure 5G indicates that Rac1-
TPase activity/protein expression was up-regulated to 362
98% in AF compared with SR (p  0.05). The Rac1
ctivity of the human left atria directly correlated with their
MA-stimulated NADPH oxidase activity (R  0.55, p 
.05).
iscussion
n summary, the study shows that the small G protein Rac1
TPase contributes to the signal transduction during AF.
ice with chronic activation of Rac1 in the heart developed
F with age—representing a novel mouse model for
hronic AF. Neither old WT mice nor old mice with left
entricular hypertrophy and secondary atrial enlargement
fter TAC develop AF. Statin treatment, which reduces
ac1 activity, was able to decrease the incidence of AF.
nalysis of human left atrial myocardium revealed that
Characteristics of RacET Treated With Statin
Table 2 Characteristics of RacET Treated W
RacET10
Heart rate (beats/min) 243.3
Mouse (g) 39.6
Tibia (mm) 18.2
Heart (mg) 238.1
Atria (mg) 19.4
LV (mg) 155.7
RV (mg) 26.3
Pulmonary congestion (l) 164.3
Hepatic congestion (l) 1,686.2
Heart (mg)/tibia (mm) 14.3
Atria (mg)/tibia (mm) 1.0
Atria (mg)/heart (mg)/tibia (mm) 4.5
Ten-month-old RacET mice (RacET10) compared with RacET10 treat
n  10 to 15.
LV  left ventricle; RV  right ventricle.ac1 GTPase and NADPH oxidase activity are up- tegulated in patients with AF compared with patients in SR
ith equal atrial diameters.
Rac1 GTPase has been shown to participate in signalling
athways of left ventricular hypertrophy (10–12). Rac1 is
ecessary for the activation of the NADPH oxidase com-
lex, a major source of myocardial superoxide production
12). In AF, oxidative damage contributes to altered myo-
brillar energetics and contractile dysfunction (4). An ani-
al model of rapid atrial pacing in pigs demonstrated that
NADPH oxidase mediates increased superoxide produc-
ion in the LA (5). In isolated myocytes from human right
trial appendages, NADPH oxidase and, to a lesser extent,
ysfunctional nitric oxide synthase were shown to contrib-
te to superoxide production in AF (13). The NADPH
xidase-derived ROS might have several pathologic effects
n the atrial myocardium including oxidative degradation of
ndocardial nitric oxide, local activation of coagulation
ascade components and prothrombotic molecules such as
AI-1 and tissue factor facilitating–thrombus formation,
nduction of fibrosis, inflammatory responses, and alteration
f ion channel function (3–5,13). To test whether Rac1
ctivation would contribute to the pathogenesis of AF, we
tudied old mice with cardiac-specific transgenesis of con-
titutively active V12Rac1 (10). The RacET mice showed
ncreased NADPH oxidase activity. The main novel obser-
ation was that RacET mice develop AF. At the ages of 10
onths and 16 months, respectively, 44% and 75% of
acET displayed AF on ECG. This parallels the natural
istory of AF, which is characterized by an increased
revalence with age (1). Aging of RacET mice was associ-
ted with increased size of the atria but not the ventricles.
eft ventricular weight was greater in 10-month-old com-
ared with 16-month-old RacET, demonstrating an effect
f the transgen in the atria. This observation is supported by
ontrol experiments characterizing the long-term effects of
ressure-induced left ventricular hypertrophy. Transaortic
onstriction results in Rac1 and NADPH oxidase activa-
tatin
RacET10  Statin SEM p Value
247.0 20.3 NS
34.6 2.5 NS
17.2 0.1 0.05
224.3 22.4 NS
17.4 2.5 NS
153.1 16.4 NS
25.1 2.7 NS
175.8 7.8 NS
1,342.0 73.4 NS
13.4 1.3 NS
1.0 0.1 NS
4.5 0.5 NS
rosuvastatin 0.4 mg/day orally for 10 months (RacET10  statin);ith S
SEM
24.9
1.5
0.3
17.4
1.3
14.4
1.6
23.4
324.7
1.5
0.1
0.3
ed withion; however, the extent of this secondary Rac1 activation
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Rac1 GTPase in AF July 24, 2007:359–67s significantly smaller compared with V12Rac transgenesis
6,9). Importantly, despite old age, continuous aortic band-
ng, LV hypertrophy and fibrosis, secondary atrial enlarge-
ent, symptoms of heart failure, and increased activity of
Figure 3 Statin Treatment Reduces
Rac1 Activity in RacET Mice
(A) Rac1-GTPase activity determined by GST–p21-activated kinase (PAK) pull-
down assays in WT, 10-month-old RacET mice (RacET10), and RacET10 treated
with rosuvastatin 0.4 mg/d orally for 10 months (RacET10  statin), n  8,
*p  0.05 versus RacET10. (B) Representative Western blots and (C) quantifi-
cation of Rac1 GTPase expression (total protein, membrane, and cytsolic frac-
tion) related to -actin in RacET10 and RacET10  statin, n  6, *p  0.05
versus RacET10. (D) Representative M-mode echocardiographic images of the
LV of RacET10 and RacET10  statin. Quantification of measurements of (E)
FS; (F) IVSd; (G) LPWd; and (H) LVDd; n  8, 5 to 8 separate measurements/
animal; *p  0.05. Abbreviations as in Figure 1.ac1 and NADPH oxidase in the ventricle, not a single
AC mouse developed AF. The atria of 16-month-old
AC mice, all of which showed SR, were larger than the
tria of 10-month-old RacET mice that exhibited AF in
4%. Statin treatment reduced the incidence of AF but did
ot reduce atrial size or the extent of fibrosis. These data
uggest that in RacET mice atrial Rac1 transgenicity sig-
ificantly contributed to the development of a substrate of
Figure 4 Statin Treatment Reduces AF
and NADPH-Oxidase Activity in RacET Mice
(A) Incidence of AF and (B) representative electrocardiography recording in
RacET10 and RacET10  statin, n  10 to 15. (C) Representative Sirius red
staining (10- and 100-fold magnification) and (D) quantification of interstitial
fibrosis in the LA, n  10 to 15, p  NS. (E) Atrial NADPH oxidase activity at
baseline and after exposure to Ang, 1 mol/l, 10 min, in RacET10 and
RacET10  statin; n  8, *p  0.05 versus untreated RacET10 and #p 
0.05 versus RacET10  Ang. Abbreviations as in Figure 1.
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July 24, 2007:359–67 Rac1 GTPase in AFF that is at least in part independent of atrial dilatation
nd fibrosis.
The RacET mice show that altered Rac1-mediated signal
ransduction contributes to the pathogenesis of AF. How-
ver, AF itself produces changes in atrial function and
tructure that are likely to alter Rac1 function (14). The
acET model does not provide information regarding the
xtent to which the perpetuation of AF is dependent on
ac1 activity. We speculate that the basis for the Rac1-
ediated atrial phenotype is likely to be a combinatorial
ffect of postnatal development, transgene expression, and
eactive signalling mechanisms. The creation of a mouse
odel of conditional cardiac Rac1 transgene expression
ould help to overcome some of these limitations of the
acET mice.
Several mouse models of increased susceptibility for the
nduction (e.g., by pacing) of atrial arrhythmias have been
eported (15–18). The RacET mice are unique compared
ith these models, because they spontaneously develop AF,
o other arrhythmia was recorded, and the AF was persis-
ent. The other known mouse models that exhibit AF are
haracterized by increased mortality, lethal phenotype, or
evere left ventricular pathology (19–24). In contrast, the
atient Characteristics
Table 3 Patient Characteristics
SR SEM AF SEM p Value
n 7 8
Male (female) 5 (2) 4 (4)
Age (yrs) 65.0 2.5 73.4 5.9 NS
Height (cm) 172.0 2.7 176.12 2.3 NS
Weight (kg) 76.6 4.2 85.0 3.5 NS
LA (mm) 52.7 4.0 52.14 3.8 NS
LVEF (%) 58.3 8.1 64.5 6.6 NS
LVESd (mm) 42.5 5.3 35.2 2.0 NS
LVEDd (mm) 58.0 4.7 51.3 2.8 NS
FS (%) 30.2 5.2 32.3 1.2 NS
IVSd (mm) 11.2 0.6 13.2 1.0 NS
LVPWd (mm) 11.5 0.7 12.2 1.2 NS
Arterial hypertension 5 7
Smoking 1 4
Diabetes 1 1
Family history of CAD 0 3
Hyperlipidemia 2 0
Beta-blocker 4 5
ACE inhibitor 4 4
AT1-antagonist 1 1
Calcium antagonist 1 0
Diuretics 5 7
Nitrate 0 1
Digitalis 0 0
Amiodaron 0 0
Sotalol 0 0
Statin 2 0
CE angiotensin-converting enzyme; CAD coronary artery disease; FS fractional shortening;
VSd  interventricular septum; LA  left atrium; LVEDd  left ventricular end-diastolic diameter;
VEF  left ventricular ejection fraction; LVESd  left ventricular end-systolic diameter; other
bbreviations as in Table 1.acET mice studied here show a normal life span and nobvious extracardiac pathology. RacET exhibit only mild
V hypertrophy, and pulmonary or hepatic congestion was
ot different from WT. In summary, compared with the
elatively few other mouse models with atrial arrhythmias,
Figure 5 Correlation of AF With Rac1 in Human LA
(A) Representative Sirius red staining (10- and 100-fold magnification) and
(B) quantification of interstitial fibrosis in LA of patients with sinus rhythm (SR)
or AF who underwent cardiac surgery, n  7 to 8, *p  0.02. (C) NADPH oxi-
dase activity determined in unstimulated LA of patients in SR or AF and after
treatment with Ang, 1 mol/l, 10 min, and phorbol-12-myristate13-acetate
(PMA), 1 mol/l, 10 min; n  7 to 8, *p  0.01. (D) Representative Western
blots of Rac1 GTPase expression (total protein, membrane and cystolic fraction
and Rac1-PAK pull down). (E) Quantification of Rac1 total protein expression
related to -actin, *p  0.01; (F) membrane content of Rac1, *p  0.01;
(G) Rac1-GTPase activity determined by GST-PAK pull-down assays, *p  0.03;
n  7 to 8. Abbreviations as in Figure 1.
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Rac1 GTPase in AF July 24, 2007:359–67acET provide a more specific model for the study of AF.
ging is an important factor for the development of AF in
he RacET, paralleling the increased incidence of AF in
lderly humans. It seems possible that other mouse models
f increased cardiac oxidative stress or inflammation might
evelop AF if studied for longer periods of time (e.g., 1.5
ears).
In addition to superoxide produced by the NADPH
xidase, further downstream effects and protein interactions
f Rac1 signalling such as PAK and Src or Rho family
embers are likely to contribute to cellular transformation.
nterestingly, a recent study demonstrated that localization
f the gap junction protein connexin 43 was determined
hrough the Rac1 pathway downstream of N-cadherin in
ardiac myocytes (25). Information from transgenic mice
ith atrial arrhythmias will be helpful to further elucidate
ownstream effects of Rac1 and NADPH oxidase. Candi-
ates are inflammatory cytokines and growth factors
15,17,21), extracellular matrix, cell–cell interactions, and
embrane proteins (19) as well as regulators of potassium
nd calcium currents (16,19,20,24).
Signal transduction during AF substantially differs be-
ween atria and ventricles (e.g., several current pharmaco-
ogical agents for the treatment of AF are limited by
entricular pro-arrhythmia) (26). In addition, a recent
icro-array analysis of a pig model of AF suggested that
enomic changes differ between the right and the left atrium
27). Atrial fibrillation is usually initiated and maintained in
he LA, because the cycle length is shorter in the left
ompared with the right atrium during AF. However, the
vailable information on signal transduction during AF in
uman LA is limited. We therefore compared samples of
he LA from patients in SR and permanent AF undergoing
itral valve surgery. The atria of both groups were only
oderately enlarged and did not differ in size. Left atrium
f AF patients exhibited increased interstitial fibrosis as an
ndicator of structural remodeling, in agreement with pre-
ious studies (14,28). The study demonstrates that the left
tria of patients with AF are characterized by a marked
p-regulation of the membrane expression and activity of
ac1 that correlates directly with increased sensitivity of
ADPH oxidase activity.
The HMG-CoA reductase inhibitors (statins), in addi-
ion to inhibiting cholesterol synthesis, down-regulate
ac1-GTPase activity by reducing isoprenylation and trans-
ocation of Rac1 to the cell membrane (29). Animal models
ave demonstrated that inhibition of Rac1 by statin treat-
ent decreases NADPH oxidase–induced superoxide pro-
uction in cardiac myocytes and reduces left ventricular
ypertrophy (6,7,9,11,12,29). On the basis of these data, we
ested the effect of long-tern statin treatment on atrial
athology in RacET mice. Statin treatment was able to
educe Rac1 activity despite overexpression of constitutively
ctive V12Rac the transgenic hearts. Statin treatment of
acET for 10 months did not alter the size of atria orentricles. Echocardiography showed a small improvementf fractional shortening and a reduction of wall thickness.
trial collagen content was not reduced. However, inhibi-
ion of Rac1 activity by statin treatment was associated with
50% reduction of the incidence of AF. We believe that in
ddition to inhibition of Rac1, the effect of statins on
renylation of other proteins as well as anti-inflammatory
ffects of statins are likely to contribute to the observed
ffects. The data are in agreement with recent findings in
ogs, where simvastatin suppressed tachypacing-induced
hortening of atrial refractoriness (30) and atorvastatin
revented maintenance of AF in a model of sterile pericar-
itis (31). Furthermore, several lines of clinical evidence
upport an antiarrhythmic effect of statins in AF, demon-
trating reduction of AF in patients with coronary disease,
fter surgery and after electrical cardioversion, and in
atients with paroxysmal AF. The recent ARMYDA-3
Atorvastatin for Reduction of MYocardial Dysrhythmia
fter cardiac surgery) study prospectively showed that statin
reatment prevents postoperative AF (32–34). Our data
emonstrate that inhibition of Rac1 GTPase represents an
mportant molecular mechanism underlying these effects.
e speculate that inhibition of Rac1 signalling might
ignificantly contribute to other anti-AF treatment strate-
ies (e.g., by inhibitors of the aldosterone-renin-angiotensin
ystem) (35).
In summary, left atria of patients with AF exhibit
p-regulation of Rac1 correlating with increased NADPH
xidase activity. In mice, chronic cardiac overexpression of
ac1 represents a novel model for AF. Rac1 GTPase
ontributes to the pathogenesis of AF and might represent
target for the prevention and treatment of AF.
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